Lean MASLD Carries Milder Histology, Yet Prognosis Still Tracks With Fibrosis
Lean metabolic dysfunction-associated steatotic liver disease is not a benign outlier. In a multinational biopsy-based cohort spanning 41 countries, adults with normal body weight and steatotic liver disease showed less advanced histologic injury on average, but their longer-term clinical outcomes still converged with those of overweight or obese patients once fibrosis entered the picture.
The study drew from the Global MASLD project and included 18,326 adults with biopsy-confirmed disease. Mean age was 50.9 years, and 47.6% were male. Using body mass index, 6.7% of the cohort met the definition of lean MASLD. Among the 12,202 patients with waist circumference available, 6.0% were lean by that measure as well, with only moderate agreement between the two definitions. Lean MASLD appeared most frequently in Asia, where prevalence reached 11.3% by BMI and 11.7% by waist circumference.
The geographic distribution matters because it reinforces a familiar clinical trap: clinicians often equate steatotic liver disease with obesity, when in fact a substantial subset of patients present without obvious excess weight. In those patients, visceral adiposity, insulin resistance, sarcopenia, genetic susceptibility, and metabolic stress can still converge on the liver even when BMI looks reassuring.
Histologic Injury Was Less Severe, But Not Absent
Lean MASLD was associated with a lower burden of metabolic comorbidity and less advanced liver injury than overweight or obese MASLD. Type 2 diabetes was present in 38.2% of lean patients versus 48.3% of those with higher body weight. Advanced fibrosis occurred in 29.3% of lean patients compared with 37.2% in the overweight or obese group. Mean Non-Alcoholic Fatty Liver Disease Activity Score was also lower in lean MASLD, at 3.96 versus 4.41.
Those differences are clinically meaningful, but they should not be mistaken for reassurance. Nearly one-third of lean patients still had advanced fibrosis, which means a normal-weight phenotype can still conceal substantial architectural liver damage. Fibrosis reflects repeated injury and wound-healing responses in the liver; once scarring advances, the downstream risks of portal hypertension, decompensation, and cancer rise regardless of the patient’s baseline body habitus.
A lean phenotype does not exclude advanced liver disease.
Fibrosis, Not Body Size, Drove Prognosis
The outcome data separated phenotype from prognosis. Unadjusted all-cause mortality was 1.08 per 100 person-years in lean MASLD and 0.91 per 100 person-years in overweight or obese MASLD. Clinical events, a composite of hepatocellular carcinoma, hepatic decompensation, liver transplant, and death, occurred at rates of 1.51 and 1.43 per 100 person-years, respectively. After adjustment, lean status was not independently associated with all-cause mortality, with a hazard ratio of 0.90, or with clinical events, with a hazard ratio of 0.94.
The signal that mattered most came from fibrosis stage. Advanced fibrosis, defined as F3 to F4, was linked to much worse outcomes: all-cause mortality rose to 1.46 per 100 person-years versus 0.77 among those without advanced fibrosis, and the adjusted hazard ratio for death was 2.10. For clinical events, rates climbed to 3.21 versus 0.89 per 100 person-years, with an adjusted hazard ratio of 3.41.
In practical terms, the study places histology above phenotype. Body composition influences who gets MASLD and how the disease presents, but once scarring is established, prognosis is driven primarily by the extent of fibrosis. That is the feature clinicians must identify early, because fibrosis is the biologic pivot point where a largely silent metabolic liver disease begins to threaten survival.
Noninvasive Fibrosis Testing Performed Differently in Lean Patients
The study also tested how well noninvasive fibrosis tools performed across body-size categories. Fibrosis-4 was somewhat less accurate for detecting advanced fibrosis in lean MASLD than in overweight or obese MASLD, with area under the curve values of 0.76 and 0.79, respectively. The difference was small but clinically relevant because it suggests that the score may be less dependable in patients whose body size and metabolic profile fall outside the population in which the index has been most widely used.
By contrast, liver stiffness measurement by transient elastography performed better in lean patients. Its area under the curve was 0.87 in lean MASLD versus 0.83 in overweight or obese MASLD. In a setting where advanced fibrosis determines follow-up intensity, referral decisions, and the need for cancer surveillance, this stronger performance matters at the bedside. Lean patients may be precisely the group in which elastography adds the most value, because they do not present with the obvious external phenotype that tends to trigger suspicion.
The study’s findings also expose a diagnostic gap. If lean MASLD is less likely to raise clinical suspicion, then reliance on routine chemistry panels or body habitus alone will miss a meaningful number of patients with advanced disease. A normal BMI should not lower the threshold for fibrosis assessment when metabolic risk factors, steatosis, or unexplained aminotransferase abnormalities are present.
What the Data Mean for Daily Practice
This cohort supports a straightforward clinical message: lean MASLD is a distinct phenotype, but it is not a mild disease by default. Patients with normal weight had less diabetes, less inflammation-driven activity on histology, and less advanced fibrosis on average, yet their long-term outcomes were not better once adjustment accounted for the underlying disease burden. The biology behind that pattern is consistent with a fibrotic process that outlives its initial metabolic trigger.
For clinicians, the most actionable step is to focus on fibrosis detection rather than appearance. Lean patients with MASLD still need risk stratification, and liver stiffness measurement appears particularly reliable in this subgroup. FIB-4 remains useful, but its lower accuracy in lean disease means it should not be the sole gatekeeper for deciding who is safe to observe.
The study’s results also challenge a common cognitive bias: body size and liver risk are not interchangeable. In lean MASLD, the absence of obesity may delay recognition, but it does not eliminate the need to stage fibrosis, assess metabolic contributors, and identify patients who already have scarred liver tissue.
Persistent Gaps in Lean MASLD Phenotyping
Several questions remain embedded in the dataset itself. The cohort was retrospective, and lean status was defined by BMI and waist circumference, two measures that capture risk imperfectly. The moderate agreement between those definitions suggests that some patients may be classified differently depending on which anthropometric marker is used. Clinical practice will need to account for that mismatch, especially in populations where BMI may underestimate central adiposity.
Even with those limitations, the message is consistent across outcomes and testing: fibrosis severity is the driver that predicts who deteriorates. Lean MASLD should therefore prompt the same fibrosis-centered evaluation strategy used in other phenotypes, with particular attention to elastography when the clinical picture and standard laboratory scores do not align.
PMID
PubMed: 42814439
- • PubMed PMID 42814439: https://pubmed.ncbi.nlm.nih.gov/42814439/